Caribou Biosciences, Inc. (CRBU)

NMS – Real vaqt narxi. Valyuta: USD

2.03

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Kompaniya haqida

Caribou Biosciences, Inc. klinik bosqichdagi klasterli muntazam joylashtirilgan qisqa palindromik takrorlar (CRISPR) genom muharrirlash biopharmaceutical kompaniyasi sifatida ishlaydi. U yangi CRISPR gibrid RNT-DNK genom muharrirlash texnologiyasiga asoslangan genom muharrirlash platformasini taklif etadi, bu esa allogen hujayra terapiyalarining aniq genom muharrirlashini ta'minlaydi. Kompaniya Vispacabtagene Regedleucel kompaniyasini ishlab chiqmoqda, bu esa qaytalangan yoki refrakter B-hujayrali non-Hodgkin limfomasini davolash uchun 1-fazali klinik sinovda bo'lgan allogen anti-CD19 CAR-T hujayra terapiyasi; va CB-011, qaytalangan yoki refrakter ko'p miyelomani davolash uchun 1-fazali klinik sinovda bo'lgan allogen anti-BCMA CAR-T hujayra terapiyasi. Caribou Biosciences, Inc. 2011 yilda tashkil etilgan va uning shtab-kvartirasi Kaliforniyaning Berkeley shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Jennifer A. Doudna Ph.D.	Co-founder & Member of Scientific Advisory Board
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director
Dr. Tina Albertson M.D., Ph.D.	Chief Medical Officer
Mr. Ryan Fischesser	Interim Principal Accounting Officer & Controller
Mr. Sriram Ryali M.B.A.	Chief Financial Officer
Mr. Timothy P. Kelly M.B.A.	Chief Technology Officer